

## **ENGAGING PWID IN COMMUNITY BASED TREATMENT AND CARE USING A NURSE-LED, SOCIAL NETWORK MODEL**

Allardice K<sup>1</sup>, von Bibra S<sup>1</sup>, Doyle JS<sup>1,2</sup>, Dietze P M<sup>1,5</sup>, Desmond P<sup>3,4</sup>, Stoove M<sup>1,5</sup>, McBryde E<sup>1,3,7</sup>, Higgs P<sup>1,5,6</sup>, Thompson AJ<sup>3,4</sup>, Hellard ME<sup>1,2, 5</sup>

<sup>1</sup>Disease Elimination Program, Burnet Institute; <sup>2</sup>Department of Infectious Diseases, The Alfred and Monash University; <sup>3</sup>Department of Medicine, University of Melbourne; <sup>4</sup>Department of Gastroenterology, St Vincent's Health; <sup>5</sup>School of Population Health and Preventive Medicine, Monash University. <sup>6</sup>Department of Public Health, La Trobe University; <sup>7</sup>Australian Institute of Tropical Health and Medicine, James Cook University

### **Background:**

Significant reductions in future hepatitis C Virus (HCV) infection could be achieved by delivering treatment in the community to people who currently inject drugs (PWID). Marginalized PWID may have difficulty accessing mainstream services due to stigma, a lack of trust, poverty, mental health issues and incarceration. We describe an outreach nurse-led model (NLM) of HCV treatment used in the Treatment And Prevention (TAP) Study; a trial measuring the HCV prevention effectiveness of treating PWID and their injecting partners.

### **Methods:**

Specialist nurses worked out of a mobile van or primary health care service to recruit PWID and their nominated injecting partners into the study. This model facilitated rapport and trust building through regular contacts and a consistent field presence. This proved important for treatment retention and for measuring follow up outcomes. Nurses provided private, non-judgmental HCV testing and treatment, fibrosis assessment using FibroScan and harm reduction advice.

### **Results:**

Three hundred and forty four PWID and their injecting partners were screened over a three-year timeframe. Of these 225 were randomised, 100 have received treatment to date and 62 have successfully completed beyond SVR12 to the final week 84 of the study. Quality of life measures post-treatment are yet to be assessed, however many of the treated PWID have reported an improved sense of wellbeing. The support of fieldworkers, peers, local government, agencies and police has been imperative to the success of this model.

### **Conclusion:**

Despite many obstacles to the delivery of HCV treatment to this population our NLM provided a viable platform on which to build future models of care. Flexibility when scheduling appointments, timely access to reflexive testing and treatment and a consistent field presence are needed. The TAP study demonstrates the feasibility of outreach and community-based NLMs for engaging and treating PWID living with HCV.

### **Disclosure of Interest Statement:**

The TAP Study is an Investigator-initiated study supported by a research grant from Gilead Sciences